- Corporate name
BioMimetics Sympathies Inc.
- Date of establishment
November 28, 2000
- List of officers
Naoki Urushihata , Chief Executive Officer
Keisuke Onishi , Chief Technical Officer
Calvin Chen , Chief Operating Officer
Tetsuo Koike , Director
Kazuharu Tomioka , Director
Shigeo Jokura, Auditors
Takashi Sueki , Auditors(Tax accountant)
Yoshiaki Ohba , Auditors (Certified administrative procedures legal specialist)
- Capital stock
2,033,300,000 yen (as of March 2023)
- Number of employees
18 (as of March 2023)
・Research development and clinical development related to cellular medicinal products
・Licensing out of products, intellectual properties, and rights related to regenerative medicine
・Cosmetics, reagents and culture medium business based on regenerative medicine technology
・Development of regenerative medicine-related businesses
・Regenerative medicine support
TIME 24 Building 19F, 2-4-32 Aomi, Koto-ku, Tokyo 135-0064, Japan
- Telephone number
- Legal advisors
Fairness Law Office
Uchida & Samejima Law Firm
Kurahashi Law Firm
|2000||Started joint research with domestic and overseas research institutes such as Keio University and Monell Chemical Senses Center in the United States for early detection of cancer using dog to detect cancer from body odor and exhaled breath, and after conducting many studies, the technology was transferred. Later on focused on specializing in regenerative medicine.|
|2007||The regenerative medicine business entered.
Development of an animal oringin-free culture technology for mesenchymal stem cells started at full scale.
|2008||Consulting on the design and management of CPCs started to be provided to medical institutions.|
|2011||Technology for culturing high-quality mesenchymal stem cells completed.
The office relocated to the Odaiba area, Tokyo (current office).
A large-scale CPC constructed and started to be managed in the Odaiba area, Tokyo.
Culture contract business targeted at medical institutions providing regenerative medicine started.
|2013||A joint research on regenerative medicine with ROHTO Pharmaceutical Co., Ltd. started.
|2014||The corporate renamed BioMimetics Sympathies Inc.|
|2015||Licensed as a cell-processing center.
Culture contract business started under the Act on the Safety of Regenerative Medicine.
An academic-industry collaboration program kicked off at Tokyo Medical University (until March 2018)
|2016||Sales of cosmetic ingredients started.|
|2019||Sales business of culture medium expanded.|
|2020||Sales of in-house cosmetics started.|
|2021||Discovered candidate substances for treatment of COVID-19 infections (patented) and succeeded in license out to a pharmaceutical company.|
Selected for AMED public offering "FY2022 Research Program on Emerging and Re-emerging Infectious Diseases"
Established a joint ventures with China's global biotechnology company Bloomage Biotechnology Co., Ltd. (Head office: Haikou, Hainan) and multiple companies including ROHTO Pharmaceutical Co., Ltd., on Hainan Island, China.
For consultations with and inquiries regarding BioMimetics Sympathies Inc, please feel free to contact us from the designated page.